Nuclixbio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

Nuclixbio General Information

Description

Developer of nucleic acid-based intractable anticancer drugs designed to develop anticancer therapeutics using unique circular mRNA (Messenger ribonucleic acid) technology. The company focuses on intracellular delivery of these agents, aiming to target specific molecules within cells, enabling medical companies to develop treatments for previously difficult-to-reach diseases by delivering drugs directly to their site of action.

Contact Information

Website
www.nuclixbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 801, Digital-ro 33-gil 28
  • Guro-gu
  • Seoul, 08377
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 801, Digital-ro 33-gil 28
  • Guro-gu
  • Seoul, 08377
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuclixbio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private Completed Generating Revenue
2. Early Stage VC (Series A) 10-Jun-2020 Completed Generating Revenue
1. Seed Round 06-Jun-2018 $2.6M $2.6M Completed Generating Revenue
To view Nuclixbio’s complete valuation and funding history, request access »

Nuclixbio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of nucleic acid-based intractable anticancer drugs designed to develop anticancer therapeutics using unique ci
Drug Discovery
Seoul, South Korea
4 As of 2024

Shanghai, China
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nuclixbio Competitors (1)

One of Nuclixbio’s competitors is CirCode, a Venture Capital-Backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CirCode Venture Capital-Backed Shanghai, China
You’re viewing 1 of 1 competitors. Get the full list »

Nuclixbio Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

Nuclixbio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025135995-A1 Novel circular rna synthesis method using rna ligase Inactive 18-Dec-2023
WO-2024136084-A1 Nucleic acid for increasing ligation efficiency or protein expression efficiency Inactive 23-Dec-2022
WO-2023214627-A1 Novel e3 ligase ligand and use thereof Inactive 03-May-2022
WO-2023096113-A1 Novel splint dna and use thereof Inactive 25-Nov-2021
EP-3998340-A1 Aptamer specifically binding to kras protein and method for using same Inactive 10-Jul-2019 C12N15/115
To view Nuclixbio’s complete patent history, request access »

Nuclixbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuclixbio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ernest Ventures Venture Capital Minority
Korea Development Bank VC-Backed Company Minority
Midasdong-a Investment Venture Capital Minority
STIC Ventures Venture Capital Minority
To view Nuclixbio’s complete investors history, request access »

Ready to get started?

Request a free trial

Nuclixbio FAQs

  • When was Nuclixbio founded?

    Nuclixbio was founded in 2017.

  • Where is Nuclixbio headquartered?

    Nuclixbio is headquartered in Seoul, South Korea.

  • What is the size of Nuclixbio?

    Nuclixbio has 4 total employees.

  • What industry is Nuclixbio in?

    Nuclixbio’s primary industry is Drug Discovery.

  • Is Nuclixbio a private or public company?

    Nuclixbio is a Private company.

  • What is Nuclixbio’s current revenue?

    The current revenue for Nuclixbio is .

  • How much funding has Nuclixbio raised over time?

    Nuclixbio has raised $8.31M.

  • Who are Nuclixbio’s investors?

    Ernest Ventures, Korea Development Bank, Midasdong-a Investment, and STIC Ventures have invested in Nuclixbio.

  • Who are Nuclixbio’s competitors?

    CirCode is a competitor of Nuclixbio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process